Issue Date: June 30, 2014
Dimension Links With Bayer For Hemophilia
Dimension Therapeutics will work with Bayer HealthCare to develop a gene therapy for the treatment of hemophilia A based on Dimension’s adeno-associated virus technology. Dimension says its technology delivers the clotting factor gene, resulting in long-lasting expression of blood-clotting protein. Dimension, based in Cambridge, Mass., will receive $20 million up front from Bayer and could get milestone payments of up to $232 million. Separately, Dimension closed a financing round in which it raised $30 million.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society